Idarubicin (Idarubicin)

Name:Idarubicin (Idarubicin)

Indications for use:
Acute non-lymphocytic leukemia (a malignant tumor arising from blood cells) in adults. Auxiliary therapy for acute lymphocytic leukemia (blood cancer, in which the source of the tumor process is granulocytic cells / bone marrow cells, from which blood cells – lymphocytes / develop) in adults and children.

Pharmacological action:
Anthracycline antibiotic. It has an anti-blastoma (anti-cancer) effect, has an antimyotic (inhibiting cell division) and cytotoxic (damaging effect on cancer cells) effect. Violates the synthesis of nucleic acids (biologically active intracellular compounds responsible for the transmission of hereditary information), which leads to the death of cancer cells.

Idarubicin (Idarubicin) method of administration and doses:
Treatment is carried out by specialists in the field of chemotherapy. The dose and treatment regimen are determined individually and depend on the nature and characteristics of the course of the disease, dosages of other iototoxic agents and amount to 12-10-8 mg/m2. body surface intravenously for 3-5 days.
Treatment with the product should be carried out under the control of the blood picture, liver and kidney function, electrocardiogram. The drug is not recommended to be mixed with other products in the same syringe. Personnel handling the product must wear protective clothing.

Idarubicin (Idarubicin) contraindications:
Severe liver and kidney dysfunction, unidentified infections, history of myelosuppression (medical history).
During pregnancy, it is recommended to interrupt it, during lactation – cessation of breastfeeding. The drug should not be prescribed to patients with a history of heart failure, if the risk of treatment is not justified by successful results.

Idarubicin (Idarubicin) side effects:
Severe myelosuppression (suppression of bone marrow activity), cardiotoxicity (damaging effect on the heart), alopecia (complete or partial hair loss), nausea, vomiting, mucositis (inflammation of the mucous membranes), diarrhea, impaired liver function , immunosuppression (suppression of immunity / body defenses /), local necrosis (necrosis) of tissues at the site of extravasal (extravascular) administration. When taking the product, it is possible to stain the urine in red.

Release form:
Dry substance (idarubicin hydrochloride) for injection 0.005 and 0.01 g in vials.

Storage conditions:
List B. In a place protected from light.

Before using the medication“Idarubicin (Idarubicin)” must be consulted with a doctor.
The instructions are provided solely for familiarization with “Idarubicin (Idarubicin) “.

Leave a Comment

Your email address will not be published. Required fields are marked *